

In re Appln. of VENKATARAMAN, Balaji
Application No. 10/056,805

CLAIM AMENDMENTS

Cancel claims 1, 2, 4 and 6-18 and add new claims 19-30.

1. (Canceled)
2. (Canceled)
4. (Canceled)
- 6-18. (Canceled)
19. (New) A method of treating upper respiratory indications comprising administering a therapeutically effective amount of dexchlorpheniramine tannate and pseudoephedrine tannate to a human patient in need thereof.
20. (New) A method of treating upper respiratory indications comprising administering a therapeutically effective amount of dexchlorpheniramine tannate, pseudoephedrine tannate and dextromethorphan tannate to a human patient in need thereof.
21. (New) The method of claim 19, wherein the upper respiratory indications are selected from the group consisting of viral infection symptoms, cold symptoms, allergic rhinitis or other allergic reactions, runny nose, cough, post-nasal drip, rhinorrhea and sinusitis.
22. (New) The method of claim 20, wherein the upper respiratory indications are selected from the group consisting of viral infection symptoms, cold symptoms, allergic rhinitis or other allergic reactions, runny nose, cough, post-nasal drip, rhinorrhea and sinusitis.
23. (New) The method of claim 19, wherein the dexchlorpheniramine tannate and pseudoephedrine tannate are administered as an oral suspension.
24. (New) The method of claim 20, wherein the dexchlorpheniramine tannate, pseudoephedrine tannate and dextromethorphan tannate are administered as an oral suspension.
25. (New) A method of treating symptoms associated with upper respiratory conditions comprising administering a composition comprising dexchlorpheniramine tannate and pseudoephedrine tannate in an amount effective for the treatment, management or mitigation of such symptoms.

In re Appln. of VENKATARAMAN, Balaji
Application No. 10/056,805

26. (New) A method of treating symptoms associated with upper respiratory conditions comprising administering a composition comprising dexchlorpheniramine tannate, pseudoephedrine tannate and dextromethorphan tannate in an amount effective for the treatment, management or mitigation of such symptoms.

27. (New) The method of claim 25, wherein the symptoms associated with upper respiratory conditions are selected from the group consisting of cough, cold, cold-like symptoms, symptoms related to upper respiratory infections, influenza symptoms and allergic rhinitis.

28. (New) The method of claim 26, wherein the symptoms associated with upper respiratory conditions are selected from the group consisting of cough, cold, cold-like symptoms, symptoms related to upper respiratory infections, influenza symptoms and allergic rhinitis.

29. (New) The method of claim 25, wherein the dexchlorpheniramine tannate and pseudoephedrine tannate are administered orally as a liquid suspension.

30. (New) The method of claim 26, wherein the dexchlorpheniramine tannate, pseudoephedrine tannate and dextromethorphan tannate are administered orally as a liquid suspension.